Merus N.V.(MRUS) Stock Research - Grey Stern Research
Loading...

Merus N.V. (MRUS) Stock Analysis

$47.24 (-2.21%)

MRUS Financial Performance


Use the table below to view Merus N.V.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $48.31 -
52 Week Low $37.77 -
52 Week High $61.61 -
Market Cap $3.3 Billion 3/15
Gross Margin 100% 1/15
Profit Margin -100% 10/15
EBITDA margin -963% 13/15
Q4 - 2024 Revenue $9.1 Million 5/15
Q4 - 2024 Earnings -$30.9 Million 6/15
Q4 - 2024 Free Cash Flow -$66.7 Million 12/15
Trailing 4 Quarters Revenue $36.1 Million 5/15
Trailing 4 Quarters Earnings -$215.3 Million 8/15
Quarterly Earnings Growth 49% 3/15
Annual Earnings Growth -67% 12/15
Quarterly Revenue Growth 2% 5/15
Annual Revenue Growth -14% 13/15
Cash On Hand $293.3 Million 3/15
Short Term Debt $1.7 Million 12/15
Long Term Debt $8.2 Million 12/15

Merus N.V. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Merus N.V.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/15
PS 92.37 4/15
PB 5.15 4/15
PC 11.38 5/15
Liabilities to Equity 0.21 10/15
ROA -0.28 6/15
ROE -0.33 5/15
Current Ratio 5.81 6/15
Quick Ratio 3.98 8/15
Long Term Debt to Equity 0.01 13/15
Debt to Equity 0.02 11/15
Burn Rate 9.26 2/15
Cash to Cap 0.09 11/15
CCR 2.16 1/15
EV to EBITDA -34.68 15/15
EV to Revenue 84.53 3/15

Company Details

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

CEO: Dr. Ton Logtenberg

Website: https://www.merus.nl

Address: Yalelaan 62 Utrecht, UTRECHT

Exchange: NASDAQ Global Market

Industry: Biotechnology

Merus N.V. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Merus N.V.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Kura Oncology, Inc. KURA $633.1 Million
Protagonist Therapeutics, Inc. PTGX $3.2 Billion
AnaptysBio, Inc. ANAB $523.8 Million
Syndax Pharmaceuticals, Inc. SNDX $1.2 Billion
Crinetics Pharmaceuticals, Inc. CRNX $3.2 Billion
Replimune Group, Inc. REPL $833.3 Million
Sutro Biopharma, Inc. STRO $63.2 Million
Larimar Therapeutics, Inc. LRMR $162.1 Million
Vaxcyte, Inc. PCVX $9.6 Billion
Kronos Bio, Inc. KRON $53.1 Million
Cerevel Therapeutics Holdings, Inc. CERE $8.2 Billion
Inhibrx, Inc. INBX $207.7 Million
Lyell Immunopharma, Inc. LYEL $170.8 Million
Anebulo Pharmaceuticals, Inc. ANEB $66.1 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
MRUS Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 9.1 Million -$30.9 Million
Q3 2024 $ 11.8 Million -$99.9 Million
Q2 2024 $ 7.3 Million -$50.0 Million
Q1 2024 $ 7.9 Million -$34.5 Million
Q4 2023 $ 8.9 Million -$60.2 Million
Q3 2023 $ 11.0 Million -$23.0 Million
Q2 2023 $ 10.5 Million -$32.0 Million
Q1 2023 $ 13.5 Million -$39.7 Million

View All

MRUS Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $293.3 Million $782.7 Million $9.9 Million $647.9 Million
Q3 2024 $433.0 Million $844.7 Million $1.8 Million $703.3 Million
Q2 2024 $629.5 Million $892.2 Million $11.0 Million $746.8 Million
Q1 2024 $178.2 Million $498.1 Million $11.5 Million $349.4 Million
Q4 2023 $205.0 Million $458.5 Million $12.2 Million $356.3 Million
Q3 2023 $241.9 Million $492.2 Million $12.1 Million $393.4 Million
Q2 2023 $101.1 Million $363.6 Million $1.6 Million $257.4 Million
Q1 2023 $102.6 Million $338.5 Million $13.2 Million $217.5 Million

View All

MRUS Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 -$66.7 Million -$20,000 -$139.7 Million
Q3 2024 -$80.7 Million -$114,152 -$195.7 Million
Q2 2024 $4.3 Million -$1.5 Million $451.3 Million
Q1 2024 -$44.5 Million -$63,000 -$26.9 Million
Q4 2023 -$34.8 Million $73,937 -$36.8 Million
Q3 2023 -$27.6 Million -$39,000 $140.8 Million
Q2 2023 $300 $0 $300
Q1 2023 -$40.4 Million -$3.6 Million -$45.1 Million

View All